Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

LP-003

Phase 3Biologic

LLongbio Pharma

LP-003 is one of 95 biologic programs targeting Allergic Asthma. It is currently in Phase 3.

3

Indications

8

Total Trials

5

Active Trials

94

Competitors

Pipeline

Status by Indication[3][1]

Indication

Allergic AsthmaActive, not recruiting

Chronic Rhinosinusitis With Nasal PolypsActive, not recruiting

Seasonal Allergic RhinitisActive, not recruiting

Allergic AsthmaPhase 2

Active, not recruiting

Chronic Rhinosinusitis With Nasal PolypsPhase 2

Active, not recruiting

Seasonal Allergic RhinitisPhase 3

Active, not recruiting

Competition

Competitive Landscape

122 competitors in Seasonal Allergic Rhinitis

#DrugCompanyPhaseTrials

Alvesco

AAzurity Pharmaceuticals

Xolair

Qvar

SSchering-Plough

Bilaxten

MMenarini International Operations Luxembourg SA

Sudafed

Comparator: Statins

Neo-Synephrine

EExela Pharma Sciences, LLC.

REGN5715

REGN5713

GW685698X

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 1/2Active, not recruiting

Single Dose

NCT07148557

Q4 2026

Phase 1Active, not recruiting

Adult Subject

NCT06604949

Phase 3Active, not recruiting

Seasonal Allergic Rhinitis

NCT07291284

Q3 2027

Phase 2Not yet recruiting

Chronic Rhinosinusitis With Nasal Polyps

NCT07313917

Q3 2029

Phase 2Recruiting

Allergic Asthma

NCT07342803

Clinical

Trials by Indication[1]

Seasonal Allergic Rhinitis2 trials

Efficacy and Safety of LP-003 in Moderate-to-severe Seasonal Allergic Rhinitis Adult

Completed·LLongbio Pharma·Phase 2·NCT06046391·180 enrolled

Efficacy and Safety of LP-003 Injection in Patients With Moderate to Severe Seasonal Allergic Rhinitis

Active, not recruiting·LLongbio Pharma·Phase 3·NCT07291284·546 enrolled

Single Dose1 trial

A Study of Single Dose of LP-003 in Adolescent Subjects

Active, not recruiting·LLongbio Pharma·Phase 1/2·NCT07148557·6 enrolled

Adult1 trial

A Study of Single and Multiple Doses of LP-003 in Healthy Adult Participants

Completed·LLongbio Pharma·Phase 1·NCT06294288·60 enrolled

Efficacy and Safety1 trial

Efficacy and Safety of LP-003 in Patients With CSU Who Remain Symptomatic Despite Antihistamine (H1) Treatment

Completed·LLongbio Pharma·Phase 2·NCT06228560·202 enrolled

Adult Subject1 trial

A Study of Single Dose of LP-003 in Healthy Adult Subjects

Active, not recruiting·LLongbio Pharma·Phase 1·NCT06604949·12 enrolled

2 more indications

Allergic Asthma1 trial

Efficacy, Safety, and Pharmacokinetics of LP-003 Injection in Allergic Asthma Patients

Recruiting·LLongbio Pharma·Phase 2·NCT07342803·200 enrolled

Chronic Rhinosinusitis With Nasal Polyps1 trial

A Study to Evaluate the Efficacy and Safety of LP-003 Injection in Patients With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)

Not yet recruiting·LLongbio Pharma·Phase 2·NCT07313917·150 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for LP-003. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — LP-003 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for LP-003. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Longbio Pharma company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 3[1]
Company: LLongbio Pharma

Related News